According to our (Global Info Research) latest study, the global Favipiravir API market size was valued at US$ 1709 million in 2025 and is forecast to a readjusted size of US$ 2301 million by 2032 with a CAGR of 4.4% during review period.
Favipiravir API is a broad-spectrum antiviral drug with the chemical name 6-fluoro-3-hydroxy-pyrazine-2-carboxamide. It acts on the viral RNA-dependent RNA polymerase, accelerating virus clearance to alleviate viral infections. As an Active Pharmaceutical Ingredient (API) in the pharmaceutical industry, Favipiravir is used to treat diseases caused by various RNA viruses.
This report is a detailed and comprehensive analysis for global Favipiravir API market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Favipiravir API market size and forecasts, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2021-2032
Global Favipiravir API market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2021-2032
Global Favipiravir API market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2021-2032
Global Favipiravir API market shares of main players, shipments in revenue ($ Million), sales quantity (Tons), and ASP (US$/Ton), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Favipiravir API
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Favipiravir API market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Chunghwa Chemical Synthesis & Biotech, TODACO, Tagoor Laboratories, Biophore, Lee Pharma, Forewin Pharma, Senova Technology, Zhejiang Hengkang Pharmaceutical, Maithili Life Sciences, Hangzhou HETA Pharm & Chem, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Favipiravir API market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Purity ≥ 98%
Purity < 98%
Market segment by Application
Pharmaceuticals
Scientific Research
Others
Major players covered
Chunghwa Chemical Synthesis & Biotech
TODACO
Tagoor Laboratories
Biophore
Lee Pharma
Forewin Pharma
Senova Technology
Zhejiang Hengkang Pharmaceutical
Maithili Life Sciences
Hangzhou HETA Pharm & Chem
Aurore Life Sciences
Bajaj Healthcare
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Favipiravir API product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Favipiravir API, with price, sales quantity, revenue, and global market share of Favipiravir API from 2021 to 2026.
Chapter 3, the Favipiravir API competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Favipiravir API breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Favipiravir API market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Favipiravir API.
Chapter 14 and 15, to describe Favipiravir API sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Favipiravir API. Industry analysis & Market Report on Favipiravir API is a syndicated market report, published as Global Favipiravir API Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Favipiravir API market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.